Phase 2/3: ?Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of BHV-3000 (rimegepant) Orally Disintegrating Tablet (ODT) for the Acute Treatment of Temporomandibular Disorders (TMD)
|Effective start/end date||1/1/22 → 8/31/23|
- BIOHAVEN PHARMACEUTICALS LLC
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.